Phase 1 Study of the MDM2 Antagonist RO6839921 in Patients With Acute Myeloid Leukemia

Investigational New Drugs - Netherlands
doi 10.1007/s10637-020-00907-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

A New Peptide Vaccine OCV-501: In Vitro Pharmacology and Phase 1 Study in Patients With Acute Myeloid Leukemia

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2017English

AML1 (Acute Myeloid Leukemia 1)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2010English

Superior Anti-Tumor Activity of the MDM2 Antagonist Idasanutlin and the BCL-2 Inhibitor Venetoclax in P53 Wild-Type Acute Myeloid Leukemia Models

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2016English

Challenges in Treating Older Patients With Acute Myeloid Leukemia

Journal of Oncology
Oncology
2010English

The mTOR Inhibitor Everolimus in Combination With Azacitidine in Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Phase Ib/Ii Study

Oncotarget
Oncology
2016English

A Randomised Phase II Study of Interleukin-1 Receptor Antagonist in Acute Stroke Patients

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2005English

A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2014English

How I Treat Older Patients With Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy